Bacteriophages as therapeutic and prophylactic means: Summary of the soviet and post soviet experiences

Current Drug Delivery

Volumn 13, Issue 3, 2016, Pages 309-323

  Chanishvili, Nina ^a  

^a George Eliava Institute for Bacteriology   (Georgia)

Author keywords

Bacteriophage (phage); Multi drug resistance; Phage therapy

Indexed keywords

ANTIBIOTIC AGENT; CEFAZOLIN; CHLORTETRACYCLINE; CIPROFLOXACIN; GENTAMICIN; NALIDIXIC ACID; PENICILLIN DERIVATIVE; STREPTOMYCIN; VIROTHERAPY AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIOPHAGE; CHOLERA; CLINICAL PRACTICE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS; SHIGELLOSIS; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCAL BACTERIOPHAGE; STAPHYLOCOCCUS INFECTION; TYPHOID FEVER; URINARY TRACT INFECTION; VIBRIO CHOLERAE; VIROTHERAPY; ANIMAL; BACTERIAL INFECTIONS; HISTORY; PHAGE THERAPY;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; PHAGE THERAPY;

EID: 84973601876     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/156720181303160520193946     Document Type: Review

References (124)

1. The bacterial challenge: time to react - A call to narrow the gap between multidrug-resistant bacteria in the EU and the development of new antibacterial agents. ECDC/EMEA JOINT Technical Report. www.ecdc.europa.eu; www.emea.europa.eu (Accessed May 25, 2015).
2. Phage therapy, a public health issue (Doc. 13480, 08 April 2014). assembly.coe.int (Accessed May 25, 2015).
3. Report to the President and “National strategy for combating antibiotic resistant bacteria”. http://www.cdc.gov/media/dpk/2014/dpkcarb.html (Accessed May 25, 2015).
4. Wommack, K.E.; Colwell, R.R. Virioplankton, pp. viruses in aquatic ecosystems. Microbiol. Mol. Biol. Rev., 2000, 64, 69-114.
5. Orlova, E.V. In: Bacteriophages; Ipek Kurtboke, Ed; InTech., 2012, pp.3-30.
6. Sharov G. Antibiotics, bacteria and bacteriophages. Nauka i Zhizn (Science and Life), 1915, 8. www.nkj.ru/archive/articles/6823 (Accessed August 23, 2015).
7. Brussow H. In: Bacteriophage Genetics and Molecular Biology; Grath S.M. and van Sinderen D., Ed; Caister Acedmic Press, UK, 2007, p. 173.
8. Twort, F. An investigation on the nature of ultramicroscopic viruses. Lancet, 1915, 11, 1241.
9. Summers, W. C. Bacteriophage therapy. Annu. Rev. Microbiol., 2001, 55, 437-451.
10. Summers, W. C. Felix d’Herelle and the Origins of Molecular Biology, Yale University Press: New Haven, CT, 1999.
11. Sulakvelidze, A.; Alavidze, Z.; Morris, J. G., Jr. Bacteriophage Therapy. Antimicrob. Agents Chemother., 2001, 45, 649-659.
12. Chanishvili, N., Chanishvili, T., Tediashvili, M., Barrow, P.A. Phages and their applications against drug resistant bacteria. J Chem Technol Biotechnol., 2001, 76, 689-99.
13. Chanishvili, N. A Literature Review on the Practical Application of Bacteriophage Research, Nova Science Publishers, N.Y, 2012.
14. Chanishvili, N. Phage therapy - History from Twort and d’Herelle through Soviet experience to current approaches. Adv. Virus Res., 2012, 83, 3-40.
15. Hausler, T. Viruses vs. Superbugs; MacMillan: New York, 2008.
16. Bruynoghe, R., and Maisin, J. Essais de the/rapeutique au moyen du bacteriophage. C.R. Soc. Biol., 1921, 85, 1120-1121.
17. Costa, C. J. Le traitement des dysenteries bacillaires par le bacteriophage. C.R. Soc Biol., 1924, 91, 845.
18. Alessandrini, A.; Doria, R. Il batteriofago nella terapia del tifo addominale. Policlinico, Sez Prat., 1924, 31, 109.
19. Compton, A. Antidysentery bacteriophage in treatment of dysentery: A record of 66 cases treated, with inferences. Lancet, 1929, 2, 273.
20. Rice, T. BUse of bacteriophage filtrates in treatment of suppurative conditions: Report of 300 cases. Am. J. Med. Sci., 1930, 179, 345-360.
21. Parfitt, T. Georgia: An unlikely stronghold for bacteriophage therapy. Lancet, 2005, 365, 2166-2167.
22. d'Herelle, F. Sur un microbe invisible antagoniste des bacilles dysentériques. C. R. Acad. Sci. (Paris) 1, 1917, 65, 373-375.
23. Kazhal, N.; Iftimovich, R. From the history of fight against bacteria and viruses. Nauchnoe Izdatelstvo: Bucharest, Romania, 1968.
24. Hankin, E. H. L’action bactericide des eaux de la Jumna et du Gange sur le vibrion du cholera. Ann. Inst. Pasteur, 1896, 10, 511.
25. Adhya, S.; Merril, C. The road to phage therapy. Nature, 2006, 443:754-755.
26. Gamaleya, N. F. (Bacterial lyzins: The enzymes destroying bacteria. Russ. Arch. Pathol. Clin. Med. Bacteriol., 1898, 6, 607-613.
27. d’Herelle, F. Bacteriophage and Phenomenon of Recovery; TSU Press: Tbilisi, Georgia, 1935.
28. Georgadze, I. A.; Makashvili, E. G., George Eliava. In: The Georgian Soviet Encyclopedia, 1979, 4, p. 125.
29. Schless, R. A. Staphylococcus aureus meningitis: Treatment with specific bacteriophage. Am. J. Dis. Child., 1932, 44, 813-822.
30. Stout, B. F. Bacteriophage therapy. Texas State J. Med., 1933, 29, 205-209.
31. Dublanchet, A.; Bourne, S. The epic of phage therapy. Can. J. Infect. Dis. Med. Microbiol., 2007, 18, 15-18.
32. Eaton, M. D.; Bayne-Jones, S. Bacteriophage therapy: Review of the principles and results of the use of bacteriophage in the treatment of infections. JAMA, 1934, 23, 1769-1939.
33. Krueger, A. P.; Scribner, E. J. Bacteriophage therapy. II. The bacteriophage: Its nature and its therapeutic use. JAMA, 1941, 19, 2160-2277.
34. Rakieten, M. L. Studies with Staphylococcus bacteriophage. I. The preparation of polyvalent Staphylococcus bacteriophage. Yale J. Biol. Med., 1932, 4, 807-818.
35. Kokin, G. A. Use of bacteriophages in surgery. Soviet Medicine “Sovietskaya Meditsina”, 1941, 9, 15-18.
36. Krestovnikova, V. A. Phage treatment and phage prophylactics and their approval in the works of the Soviet researchers. J. Microb. Epidemiol. Immunol., 1947, 3, 56-65.
37. Kokin, G. A. Phage therapy and phage prophylaxis of gas gangrene. In: Experience of the Soviet Military Medicine during the Great Patriotic War 1941-1945; Medgiz, Moscow; 1946, 3, pp. 56-63.
38. Tsulukidze, A. P. An Experience of use of bacteriophages in the conditions of war traumatism; Gruzmedgiz: Tbilisi, Georgia, 1941.
39. Karamov, S. Experience of phage therapy for treatment of typhoid fever. In: Selected Articles of Azerbaijani Institute of Epidemiology and Microbiology, Baku, Azerbaijan SSR; 1938, 6, pp. 101-105.
40. Sapir, I. B. Observations and recommendations related to phage therapy of dysentery. In: Proceedings of the Moscow Institute of Infectious Diseases after I.I. Mechnikov, 1939, pp. 135-151.
41. Appelmans, R. Le dosage du bactériophage. C.R. Soc. Biol., 1921, 85, 1098-1099.
42. Ionov, I. D.; Erez, S. L.; Goldenberg, E. Y. Specific therapy of dysentery. In: Variability of Microorganisms and Bacteriophage Research; In: Proceedings of the Scientific Conference, 1936, Kiev, Ukraine; 1939, pp. 337-346.
43. Golubtsov, G. V. Sero- and phage- therapies of dysentery among babies and infants. In: Selected Articles of the 1st Scientific Conference of the Bashkir Medical University, March 23-25, 1939: Ufa, Russia; 1940. pp. 13-16.
44. Lipkin, Y.D.; Nikolskaya, L.V. Experience of phage therapy of dysentery. In: Selected Articles of the Kuibishev Red Army Military- Medical Academy; KRAMMA: Kuibishev, Russian SSR; 1940. Vol. 4, pp. 193-198.
45. Vlasov, K. F.; Artemenko, E. A. Treatment of chronic dysentery. Soviet Med. “Sovetskaya Medicina”, 1946, 10, 22-28.
46. Mikaelyan, V. G. Phage therapy of the bacterial carriers of typhoid bacteria. In: Proc. Yerevan Med. Institute; YMI: Yerevan, Armenian SSR; 1949, Vol. 6, pp. 54-59.
47. Gnutenko, M. P. Treatment of S. typhi and paratyphi bacterial carriers with bacteriophages. J. Microbiol. Epidemiol. Immunol., 1951, 5, 56-60.
48. Belikova, M.A. Experience of phage prophilaxis of summer dysentery among the young children performed in the city Stalinbgrad. J. Microbiol. Epidemiol. Immunol., 1941, 5-6, 142.
49. Blankov, B.I. Analysis of the results of phage prophylaxis of dysentery among the contacting people. Report # 1. J. Microbiolo. Epidemiol., Immunol., 1941, 5-6, 125.
50. Blankov, B.I.; Zherebtsov, I.D. Experience on the multiple phaging of the contacting population in the fight against dysentery. Report # 2, J. Microbiol. Epidemiol. Immunol., 1941, 5-6:131.
51. Karpov, S. P. The specific bacteriophage in relation to the issue of combating typhoid and paratyphoid diseases. J. Microbiol. Epidemiol. Immunol., 1946, (1-2), 40-44.
52. Kagan, M. I.; Kuznetsova, E. V.; Teleshevskaya, E. A. To the issue of epidemic effectiveness of the planned phaging in the day nurseries. J. Microbiol. Epidemiol. Immunol., 1964, 7, 89-102.
53. Florova, N. N.; Cherkass, F. K. Results of mass application of polyvalent dysenteric bacteriophage. J. Microbiol. Epidemiol. Immunol., 1965, 3, 118-125.
54. Agafonov, B. I.; Khokhlov, D. T.; Zolochevsky, M. A. Epidemiology of typhoid-paratyphoid infections and their prophylactics. Military- Med. J. 1984, 6, 36-40.
55. Anpilov, L. I.; Prokudin, A. A. Prophylactic effectiveness of the dry polyvalent dysentery bacteriophage in organized communities. Military-Med. J., 1984, 5, 39-40.
56. Melnik, M. I.; Nikhinson, I.M.; Khastovich, R. I. Phage prophylaxis of dysentery. In: Proceedings of the Mechnikov Institute in Kharkov; Kharkov, Ukrainian SSR; 1935, Vol. 1(1):MIKH.
57. Karpov S.P. Mechanism of prophylactic action of typhoidparatyphoid bacteriophages (Dynamics of phage release from the organism of perenterally “phaged” white mice. J. Microbiol. Epidemiol. Immunol., (JMEI), 1950, 7, 43-45.
58. Karpov S.P. and Yavorskaya B.M. Mechanism of prophylactic action of typhoid-paratyphoid bacteriophages (Dynamics of phage release from the organism of “phaged” people. J. Microbiol. Epidemiol. Immunol., (JMEI), 1949, 7, 42-43.
59. Yermolyeva Z.V. About bacteriophages and its application. J. Microbiol. Epidemiol. Immunol. (JMEI), 1939, 9, 9-17.
60. Knopov M.M.; Klyasov A.V. http://rmapo.ru/history/228-zinaidavissarionovna-ermoleva-sozdatel-pervogo-otechestvennogoantibiotika.html (Accessed on May 25, 2015).
61. Chaurina, R.A. Zianida Vissarionovna Yermolyeva, “Death by passes backyard science”, http://panov-a-w.narod.ru/stati/zilber.html (Accessed on May 25, 2015).
62. Karpov, S.P. Mechanism of prophylactic action of typhoidparatyphoid bacteriophages (Dynamics of phage release from the organism of perenterally “phaged” white mice. J. Microbiol. Epidemiol. Immunol. (JMEI); 1950, 7:43-45.
63. Karpov, S.P.; Yavorskaya, B.M. Mechanism of prophylactic action of typhoid-paratyphoid bacteriophages (Dynamics of phage release from the organism of “phaged” people. J. Microbiol. Epidemiol. Immunol. (JMEI), 1949, 7, 42-43.
64. Yermolyeva, Z.V.; Yakobson, N.M. Diagnostics of cholera and effect of phage prophylaxis during the cholera outbreaks. In: Achievements of the Soviet medicine during the years of the Great Patriotic War, 1943, 1, pp.50-64.
65. Podvarko A.G. Cholera. Treatment. In: Multivolume Guide in Microbiology, Clinics and Epidemiology of Infectious Diseases. Medicina: Moscow, Russia; 1964, 6, pp.245-254.
66. Babalova, E. G.; Katsitadze, K. T.; Sakvarelidze, L. A.; Imnaishvili, N. Sh.; Sharashidze, T. G.; Badashvili, V. A.; Kiknadze, G. P.; Meipariani, A. N.; Gendzekhadze, N. D.; Machavariani, E. V.; Gogoberidze, K. L.; Gozalov, E. I.; Dekanosidze N.G. On the issue of prophylactic importance of the dry dysenteric bacteriophage. J. Microbiol. Epidemiol. Immunol., 1968, 2, 143-145.
67. Sayamov, R. M. Treatment and prophylaxis of cholera with bacteriophage. Bull. WHO, 1963, 28, 361-367.
68. Kurochka, V. K.; Karniz, A. F.; Khodyrev, A. P. Experiences of implementation of preventive anti-epidemic measures in the center of intestinal infections with water transmission mechanism of morbidity. Military-Med. J., 1987, 7, 36-37.
69. Vartapetov, A Y. Bacteriophage therapy of deep form of staphylococcal dermatitis. In Bacteriophage Research In: Selected articles of Inter-Institutional conference taking place in Tbilisi on October 26-29, 1955; 1957; Tbilisi, Georgia, 1957, pp. 411-426.
70. Shvelidze K.D. Treatment of deep forms of staphylococcal dermatitis with the staphylococcal bacteriophages and some aspects of immune response. Cand. Diss. Thesis; Tbilisi State Medical University: Tbilisi, Georgia, 1970.
71. Tsulukidze, A.P. Application of phages in urology. Urology “Urologia”, 1938, 15(1), 10-13.
72. Arshba, C.; Bagdoeva, K. Application of phage therapy against colibacterial infections of urinary tract. Issues Clin. Exper. Mental Urol., 1965, 3, 7-13.
73. Shakadze, I. Study of uropathogenic E.coli strains and biological properties of their corresponding bacteriophages. Tbilisis State Medical University, Tbilisi, Georgia, 2006.
74. Application of bacteriophages preparations for treatment of the urological diseases. http://www.bionow.ru/bnows-1020-2.html (Accessed on May, 2015).
75. Musin, D.R. Prophylaxis and treatment of the consequences after the contact lithotripsy of kidney stones in cases of infected urolithiasis. Cand. Diss. Saratov, Russia, 2008.
76. Perepanova, T.S.; Dubreeva, O.S.; Koliatarova, G.A.; Kondratieva, E.M.; Aiskaia, I.M.; Malysheva, V.F.; Baiguzina, F.A.; Grishkova, N.Y. The efficacy of bacteriophage preparations in treating inflammatory urogenital diseases. Urology Nefrology, 1957, 5, 14-17.
77. Kolomintsev, N.B.; Goroeinko, I.I.; Shakhmatov, V.K.; Brazhnik P.K. Treatment of urology infections with different antibiotics and specific coli-proteus bacteriophages In: Strategy and tactics of antibiotic therapy, Krasnodar, 1966 pp. 172-174.
78. Perepanova T.S. Complex treatment and prophylaxis of the hospital urology tract infections. Doct. Dss. Moscow, 1996.
79. Parfenyuk R.L. Microbiological basis for oral therapy of purulentinflammatory diseases. Cand. Diss, Moscow, Russia, 2004.
80. Prokopenko E.I. Diagnostics and complex treatment and prophylaxis of infectious consequences developed among recipients of kidney transplants. Doct. Diss. Moscow, Russia, 2005.
81. Belopolsky A.A. Ways for optimization of therapy of patients with acute cystitis in the conditions of outpatient clinic. Cand. Diss. Moscow, 2008.
82. Khawaldeh, A.; Morales, S.; Dillon, B.; Alavidze, Z.; Ginn, A.N.; Thomas, L.; Chapman, S.J.; Dublanchet, A.; Smithyman, A.; Iredell, J.R. Bacteriophage therapy for refractory Pseudomonas aeruginosa urinary tract infection. J. Med. Microbiol., 2011, 60(11), 1697-1700.
83. Zakharova, Y. A.; Nikolaeva, A.M.; Padrul, M.M. Application of bacteriophages preparations for pregnant women suffering with urology infections, BioPreparations, 2010, 2 http://www.biopreparaty-magazine.ru/articles/38_05/ (Accessed May 2015).
84. Danilova, T.M. Phage therapy of the inflammatory urogenital infections in women. Proc. Dermatol. Venerol., 1996, 5, 75.
85. Kisina, V.I.; Perepanova, T.S.; Zabirov, K.I. Phage therapy of inflammatory uro-genital women diseases. J. Dermatol. Venerol., 1996, 5, 45-48.
86. Makarova, E.L. Study clinical and biochemical indexes after phage therapy of the pregnant women suffering with pyeolonephritis. Cand. Diss. Perm, Russia, 2008.
87. Krasilnikov, I.V.; Lysko, K.A.; Otrashevskaya, E.V.; Lobastova, A.K. Bacteriophage based preparations: a brief survey of current state and future development. Siberian Med. J., 2011, 26(2/2), 33-36.
88. Veselov, A.I.; Karmanova, S.Y. Lytic activity and specificity of the commercial bacteriophages. Clin. Lab. Diagnostics, 1992, 9-10, 55-57.
89. Chushkov, Y.V. Bacteriophages in therapy and prophylaxis of infectious diseases. Med. Proc., 2011, N6. http://www.medvestnik.ru/library/article/8099
90. Alsynbaev, M.M.: Medvedev, Y. A.; Taigunov, M.M. Biopreparations and major trends for their use in therapy and ptophylaxis. Ufa, “Microgen”, 2008.
91. Sultanov, N.M. Antibacterial activity and clinical efficiency of the polyvalent purified pyobacteriophage for treatment of chronic purulent rhinosinusistis. Cand. Diss. Thesis. Ufa, Bashkir State University, 2007.
92. Zakharova, Y A.; Belokrylov, N.M.; Clinical case of treatment of the patient with osteomielitis caused by multiply resistant Pseudomonas aeruginosa and Staphylococcus aureus using page therapy method. In: Development and application prospects of medical immunobiological preparations In: Proceedings of the All-Russian Scientific-Practical Conference, Perm, Russia, 2008, pp.96-97.
93. Bochorishvili T.V. Clinical evaluation of effectiveness of various methods of immune and intravenous therapies of the generalized forms of staphylococcal infections, Cand. Diss, Tbilisi, Georgia, 1984.
94. Samsygina, G.A., Boni, E.G. Bacteriophages and phage therapy in pediatric practice. Pediatrics, 1984, 4, 67-68.
95. Samsygina, G. A. Festering Inflammatory Infections among Newborns (Etiology, Risk Factors, Clinic and Immune Diagnostic Criteria and Strategy of Treatment). Doct. Diss, Thesis, The Moscow Medical University: Moscow, Russia, 1985.
96. Chkhetia, N. Treatment of lung diseases. Cand. Diss, Tbilisi, Georgia, 1984.
97. Meladze, D.G.; Mebuke, M.G.; Chkhetia, N.S.; Kiknadze, N.Y.; Koguashvili, G.G.; Timoshuk, I.I.; Larionova, N.G.; Vasadze, G.K. Effect of the Staphylococcal bacteriophgage for treatment of purulent infections of lungs and pleura. Breast Surgery “Grudnaya Khirurgia” 1981, 1, 53-56.
98. Tavebridze, L.N. Post-traumatic treatment of the long bones. Cand. Diss., Tbilisi, Georgia, 1993.
99. Bochorishvili E. V., Chanishvili T.G., Sharashidze T.G., Nadiradze M.M., 1988. Method of treatment of the tube infertility of the inflammatory nature, Patent SU 1395331 A 1, Authors Certificate # 1395331. Report Clin. Trials, Tbilisi, Georgia, 1985.
100. Kvachadze, L.; Balarjishvili, N.; Meskhi, T.; Tevdoradze, E.; Skhirtladze, N.; Pataridze, T.; Adamia, R.; Topuria, T.; Kutter, E.; Rohde, C.; Kutateladze, M., Evaluation of lytic activity of staphylococcal bacteriophage Sb-1 against freshly isolated clinical pathogens. Microb. Biotechnol., 2011, 4, 643-650.
101. Giorkhelidze, T.; Koberidze, T.; Malkhazova, I.; Janelidze, N.; Tediashvili, M.; Chanishvili, N.; Hanlon, G.; Denyer, S. Screening results of the MRSA strains with Staphylococcus phages, In: Abstract Book of the Phage, Biology, Ecology and Therapy Meeting; Tbilisi, Georgia, June 12-15, 2008, p. 36.
102. Kokashvili, T.; Wuerzner, R.; Dorth-Holler, D.; Tediashvili, M. In Vitro efficacy of Eliava phage preparations against clinical strains of S. aureus, P. aeruginosa and E. coli isolated in Austria. In: Abstract book, III International Conference on Antimicrobial Research; Madrid, Spain, October 1-3, 2014, p. 188.
103. Vandersteegen, K.; Mattheus, W.; Ceyssens, P-J.; Bilocq, F.; De Vos, D.; Pirnay, J-P.; Noben, J-P.; Merabishvili, M.; Lipinska, U.; Hermans, K.; Lavigne, R. Microbiological and molecular assessment of bacteriophage ISP for the control of Staphylococcus aureus. Plos One, 2011, 9. DOI: 10.1371/journal.pone.0024418
104. Kutateladze, M.; Adamia, R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol., 2010, 28, 591-595.
105. Workentine, M.L.; Sibley, C.D.; Glezerson, B.; Purighalla, S.; Norgaard-Gron, J.C.; Parkins, M.D.; Rabin, H.R.; Surette, M.G. Phenotypic heterogeneity of Pseudomonas aeruginosa populations in a cystic fibrosis patient. PLoS One, 2013, 8, e60225.
106. Winstanley, C.; Langille, M.G.; Fothergill, J.L.; Kukavica-Ibrulj, I.; Paradis-Bleau, C.; Sanschagrin, F.; Thomson, N.R.; Winsor, G.L.; Quail, M.A.; Lennard, N.; Bignell, A.; Clarke, L.; Seeger, K.; Saunders, D.; Harris, D.; Parkhill, J.; Hancock, R.E.; Brinkman, F.S.; Levesque, R.C.; Newly introduced genomic prophage islands are critical determinants of in vivo competitiveness in the Liverpool Epidemic Strain of Pseudomonas aeruginosa. Genome Res., 2009, 19, 12-23.
107. Sahota J.S.; Smith, C.M.; Radhakrishnan, P.; Winstanley, C.; Goderdzishvili, M.; Chanishvili, N.; Kadioglu, A.; O’Callaghan, C.; and Clokie, M.R.J. Bacteriophage delivery by nebulization and efficacy against phenotypically diverse pseudomonas aeruginosa from Cystic Fibrosis Patients. J. Aerosol Med. Pulmonary Drug Deliv., 2015, 28, 1-8.
108. Merabishvili, M.; De Vos, D.; Verbeken, G.; Kropinski, A.M.; Vandenheuvel, D.; Lavigne, R.; Wattiau, P.; Mast, J.; Ragimbeau, C.; Mossong, J.; Scheres, J.; Chanishvili, N.; Vaneechoutte, M.; Pirnay, J-P.; Selection and characterization of a candidate therapeutic bacteriophage that lyses the Escherichia coli O104:H4 strain from the 2011 outbreak in Germany. Plos One, 2012, 7(12), e52709.
109. Goderdzishvili, M.; Alavidze, Z.; Meipariani, A.; Chkonia, I.; Dzidzishvili, L.; Kvatadze, N.; Jgenti, D.; Rigvava, S.; Dvalidze, T.; Kusradze, I.; Karumidze, N.; Nadirashvili, N.; Katsarava, R. Creation and study of antimicrobial-antifungal composite against mixed infections using biodegradable polymer as matrix. Proc. Georgian Acade. Sci., Ser. Biol., 2009, 7(3-4), 57-65.
110. Markoishvili, K.; Tsitlanadze, G.; Katsarava, R.; Morris, G.; Sulakvelidze, A. A novel sustained-release matrix based on biodegradable poly (esteramide)s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds. Intl. J. Dermatol., 2002, 41, 453-458.
111. Gorski, A.; Miedzybrodzki, R.; Borysowski, J.; Weber-Dabrowska, B.; Łobocka, M.; Fortuna, W.; Letkiewicz, S.; Zimecki, M.; Filby, G. Bacteriophage therapy for the treatment of infections. Curr. Opin. Invest. Drugs, 2009, 10, 766-774.
112. Pirnay, J.-P.; De Vos, D.; Verbeken, G.; Merabishvili, M.; Chanishvili, N.; Vaneechoutte, M.; Zizi, M.; Laire, G.; Lavigne, R.; Huys, I.; Van den Mooter, G.; Buckling, A.; Debarbieux, L., Pouillot, F., Azeredo, J., Kutter, E., Dublanchet, A., Górski, A., Adamia, R. The phage therapy paradigm: Prêt-à-porter or sur-mesure? Pharm. Res., 2011, 28, 934-937.
113. Kutter, E., De Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S., Abedon, S. T. Phage therapy in clinical practice: Treatment of human infections. Curr. Pharm. Biotechnol., 2010, 11, 69-86.
114. Villareal, L. P. Overall issues of viral and host evolution. In: Virus and Evolution of Life; I. P. Villareal, Ed., ASM Press; Washington, DC, 2005, pp. 1-28.
115. Verbeken, G., Pirnay, J.P., De Vos D., Jennes, S., Zizi, M., Lavigne, R., Casteels, M., Huys, I. Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine. Arch. Immunol. Ther. Exp. (Warsz)., 2012, 60(3), 161-72.
116. Verbeken, G.; Huys, I.; Pirnay, J-P.; Jennes, S.; Chanishvili, N.; Scheres, J.; Gorski, A.; De Vos, D.; Ceulemans, C. Taking Bacteriophage Therapy Seriously: A Moral Argument. BioMed. Res.Intl., Hindawi Publishing Corporation; 2014, Article ID 621316; http://dx.doi.org/10.1155/2014/621316 (Accessed May 25, 2015).
117. Gambashidze, P.; Khorava, A.; Azaladze, T.; Kalandarishvili, K.; Jaiani, E.; Lasareishvili, B.; Azaladze, A.; Tediashvili, M. Antitumor and adjuvant effects of phagelysates of E.coli in mice with Ehrlich carcinoma. Exper. Oncol., 2012, 34(2), 1-5.
118. Sagor, M.M.; Islam, K.K.; Raihan, A.G. Md.; Abdul-Awal, S.M.; Adhikary, P.P.; Sarker P.K.; Rakib, A.S. Md. Bacteriophages: A potential therapeutic agent. J.Med.Sc., 2005, 5(1), 1-9.
119. Borysovski, J.; Gorski, A. Is phage therapy acceptable in the immunocompromised host? Intl. J. Infectious Dis., 2008, 12, 466-471.
120. Qadir M.I. Review: phage therapy: a modern tool to control bacterial infections. Pak J Pharm Sci. 2015, 28(1), 265-70.
121. Smith, G.P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science, 1985, 228(4705), 1315-1317.
122. Lee, J-W.; Song J.; Gwang, M.P.; Lee, K.H. Nanoscale bacteriophage biosensors beyond phage display. Intl. J. Nanomed., 2013, 8, 3917-3925.
123. Singh, A.; Poshtiban, S.; Evoy, S. Recent Advances in Bacteriophage Based Biosensors for Food-Borne Pathogen Detection. Sensors, 2013, 13, 1763-1786; doi:10.3390/s130201763 (accessed May 25, 2015).
124. Pavlova, L.I.; Sumatokov, A.A.; Solodovnikov, Y.P; Nikitiuk, N.M. To the issue of use of dysenteric bacteriophage as of prophylactic mean against dysentery. J. Microbiol. Epidemiol. Immunol., 1973, 7, 27-32.